These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
380 related items for PubMed ID: 36353233
21. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis. Yang S, He W, Zhao L, Mi Y. PLoS One; 2022; 17(4):e0267025. PubMed ID: 35421174 [Abstract] [Full Text] [Related]
26. DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice. Abe M, Okada K. Contrib Nephrol; 2015; 185():98-115. PubMed ID: 26023019 [Abstract] [Full Text] [Related]
27. Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis. Huang YL, Xu XZ, Liu J, Wang PY, Wang XL, Feng HL, Liu CJ, Han X. BMC Cardiovasc Disord; 2023 Jun 09; 23(1):293. PubMed ID: 37296380 [Abstract] [Full Text] [Related]
28. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Wang Z, Sun J, Han R, Fan D, Dong X, Luan Z, Xiang R, Zhao M, Yang J. Diabetes Obes Metab; 2018 Jan 09; 20(1):113-120. PubMed ID: 28656707 [Abstract] [Full Text] [Related]
29. Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: A meta-analysis. Zhou X, Shi H, Zhu S, Wang H, Sun S. J Diabetes Investig; 2022 Mar 09; 13(3):468-477. PubMed ID: 34551206 [Abstract] [Full Text] [Related]
30. Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Gong Y, Bai X, Zhang D, Yang X, Qin Z, Yang Y, Zhou Y, Meng J, Liu X. Lipids Health Dis; 2024 May 25; 23(1):157. PubMed ID: 38796440 [Abstract] [Full Text] [Related]
31. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. Tang H, Li G, Zhao Y, Wang F, Gower EW, Shi L, Wang T. Diabetes Obes Metab; 2018 May 25; 20(5):1262-1279. PubMed ID: 29369494 [Abstract] [Full Text] [Related]
38. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Tong L, Adler S. Postgrad Med; 2018 May 25; 130(4):381-393. PubMed ID: 29667921 [Abstract] [Full Text] [Related]
39. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators. Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217 [Abstract] [Full Text] [Related]